CJC-1295 vs Tesamorelin: A Research Comparison

CJC-1295 and Tesamorelin come up together constantly in growth-hormone-axis research, and for a good reason: both are analogs of growth-hormone-releasing hormone (GHRH). That shared classification is exactly why researchers compare them — and also why they're easy to confuse. This overview lays out how they differ as research compounds. Everything here is educational and for laboratory research use only; nothing below concerns human or animal use, dosing, or outcomes.

What each one is

CJC-1295 is a synthetic analog of GHRH — specifically a modified fragment of the GHRH sequence engineered for greater stability than the native peptide. It circulates in two forms: with DAC (a Drug Affinity Complex that binds albumin to extend stability in experimental systems) and without DAC (the "no-DAC" version, closely related to the compound also called modified GRF 1-29). When a supplier lists "CJC-1295 no-DAC," they mean the shorter-acting version without the albumin-binding modification.

Tesamorelin is also a GHRH analog — a stabilized analog of the full GHRH(1-44) sequence. Structurally it is closer to the native releasing hormone than CJC-1295's shortened fragment, with a modification intended to resist enzymatic breakdown in research systems.

In short: both are GHRH analogs, but they're modeled on different portions of the GHRH sequence and stabilized in different ways.

What the research examines

This is where careful framing matters. The published literature — largely cell-culture and animal-model work — studies both compounds as GHRH-receptor-targeting analogs: how they interact with the GHRH receptor, their stability relative to native GHRH, and their behavior in models of growth-hormone-axis signaling.

What the literature does not establish — and what we won't imply — is any conclusion about effects in humans, any benefit, or any protocol. These are mechanistic findings in controlled research systems. They are the reason the compounds remain subjects of study, not evidence of an outcome you can act on. As always, read the primary literature directly rather than relying on marketing claims.

Why they're often compared

Because both are GHRH analogs studied around the same receptor and signaling axis, researchers frequently line them up to examine how structural differences — a short stabilized fragment (CJC-1295) versus a stabilized full-length analog (Tesamorelin) — translate into different stability and receptor-interaction profiles in experimental systems. It's a structure-and-stability comparison, not a claim about which one "works better" in any applied sense.

The practical differences that matter when sourcing

Set the biology aside, and what actually separates a good purchase from a risky one is identical for both compounds:

1. Independent third-party HPLC purity testing, ideally with mass-spec identity confirmation — this also confirms which CJC-1295 variant (no-DAC vs DAC) you're actually receiving. In-house claims don't count.
2. A published, lot-specific Certificate of Analysis you can read before you buy. (New to reading them? See how to read a COA.)
3. Proper storage and handling — both are typically supplied lyophilized and reconstituted for lab work. (See how to store peptides, and our free reconstitution calculator for the draw math.)
4. Honest research-use-only framing — a supplier making health or dosing claims about either compound is a red flag, not a selling point. (More on this: how to vet a research peptide vendor.)

Sourcing them as reference materials

Both are commonly supplied as research-use-only reference materials. As a disclosed example, NovaForge Labs supplies CJC-1295 (no-DAC) as a research-use-only reference material and Tesamorelin as a research-use-only reference material — each lot third-party HPLC-tested with a published Certificate of Analysis, and supplied strictly for laboratory research use only, with no claims about use in people.

The bottom line

CJC-1295 and Tesamorelin are two GHRH analogs built on different pieces of the GHRH sequence and stabilized in different ways, which is exactly why they're so often studied side by side. Know which one — and which CJC-1295 variant — you're evaluating, read the primary research rather than the marketing, and whatever you source, make the Certificate of Analysis the deciding factor.